A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy

Epilepsia

Volumn 42, Issue 10, 2001, Pages 1354-1358

  Wong, Ian C K ^a   Mawer, George E ^b   Sander, Josemir W A S ^c   Lhatoo, Samden D ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Chronic epilepsy; Lamotrigine; Pharmacoepidemiology; Seizure free Retention rate

Indexed keywords

ACETAZOLAMIDE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME;

ANTICONVULSANTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; ENGLAND; EPILEPSIES, PARTIAL; EPILEPSY; EPILEPSY, GENERALIZED; FEMALE; HUMANS; LONG-TERM CARE; MALE; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZINES;

EID: 0035160490     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.02101.x     Document Type: Article

References (26)

1. Pharmacological studies of lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies of the mechanism of action
2. New anti-epileptic drugs: A systematic review of their efficacy and tolerability
3. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy
4. Lamotrigine as an add-on drug in typical absence seizures
5. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin
6. UK lamotrigine/carbamazepine monotherapy trial group: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
7. Factors influencing the incidence of lamotrigine-related skin rash: Results of a case record survey
8. The long-term use of gabapentin, lamotrigine and vigabatrin in patients with chronic epilepsy
9. Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: Audit of outcome
10. Adverse event monitoring in lamotrigine patients: A pharmacoepidemiologic study in the United Kingdom
11. Relation between several variables
12. Non-parametric estimation from incomplete observations
13. Regression models and life tables
14. Interaction of lamotrigine with sodium valproate
15. Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy
16. Adverse reactions to new anticonvulsant drugs
17. Clinical pharmacokinetics of new anti-epileptic drugs
18. Epilepsy with myoclonic absences
19. The efficacy of valproatelamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
20. Lamotrigine and seizure aggravation in severe myoclonic epilepsy
21. Aggravation of severe myoclonic epilepsy by lamotrigine
22. Prognostic factors for longterm retention of topiramate
23. Safety review of adult clinical trial experience with lamotrigine
24. Rechallenge with lamotrigine after initial rash
25. Proposal for revised classification of epilepsies and epileptic syndromes